Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Regulatory News (SYNC)

Share Price Information for Syncona (SYNC)

Share Price is delayed by 15 minutes
Get Live Data
98.20    -0.80 (-0.81%)
Bid:
98.20
Ask:
99.10
Spread: 0.90 (0.916%)
Market Cap: £597.25m
SYNC Live PriceLast checked at - London Stock Exchange

Intraday Syncona Share Chart

Proposed changes to expense arrangements

24 Nov 2015 10:40

BACIT LIMITED - Proposed changes to expense arrangements

BACIT LIMITED - Proposed changes to expense arrangements

PR Newswire

London, November 24

BACIT LIMITED(a closed-ended investment company incorporated in Guernseywith registration number 55514)

(the "Company")

24 November 2015

Proposed changes to expense arrangements

The Company announces a proposed change to the basis on which the operating expenses of BACIT (UK) Limited, the Company’s investment manager (the “Investment Manager”), are paid with effect from 1 January 2016. The proposed change is subject to shareholder approval. 

The key features of the Company’s investment policy — that it will invest in underlying funds on a “gross return” basis, that it will invest up to one per cent. per annum of its net asset value in drug development projects and that it will donate one per cent. per annum of its net asset value to charities including the Institute for Cancer Research (“ICR”) — will remain unchanged. Both the ICR and the managers of the underlying funds in which the Company currently invests are supportive of the proposed change. 

To date, neither the Investment Manager nor the BACIT investment management team have received a fee from the Company for their investment management services. Under the proposed arrangements, the personnel costs and operating expenses of the investment management function will be covered by a new fee payable by the Company to the Investment Manager equal to 0.19% per annum of the Company’s net asset value. It is not envisaged that the Investment Manager should make a meaningful profit from the fee. Notwithstanding the proposed changes to the expense arrangements Tom Henderson will continue to provide his services as a director of the Company and as CEO of the Investment Manager free of charge. 

A circular, including a notice of an extraordinary general meeting of the Company to approve the proposed changes to the expense arrangements intended to be held at 9.30 a.m. on 11 December 2015 at the offices of Northern Trust International Fund Administration Services (Guernsey) Limited, Trafalgar Court, Les Banques, St Peter Port, Guernsey GY1 3QL will be sent to shareholders shortly. 

A copy of the circular, when published, be available on the Company's website at http://www.bacitltd.com. The Circular will also be submitted to the National Storage Mechanism and will be available for inspection at www.morningstar.co.uk/uk/nsm.

Enquiries:

Northern Trust International Fund Administration Services (Guernsey) Limited

Tel: +44 (0) 1481 745368

Date   Source Headline
5th May 202212:05 pmRNSAutolus Reports Q1 2022 Financial Results
28th Apr 20227:00 amRNSSyncona invests in £75.5 million OMass Series B
11th Apr 20227:00 amRNSAnaveon announces initial clinical data
4th Apr 202212:34 pmRNSDirector/PDMR Shareholding
1st Apr 20227:00 amRNSFreeline reports Full Year 2021 Financial Results
24th Mar 20224:11 pmRNSHolding(s) in Company
23rd Mar 20228:30 amRNSFreeline enters into ADS purchase agreement
11th Mar 20227:00 amRNSFreeline registered direct offering
10th Mar 202212:05 pmRNSAutolus Reports Full Year 2021 Financial Results
9th Mar 20224:39 pmRNSDirector/PDMR Shareholding
9th Mar 20223:09 pmRNSHolding(s) in Company
7th Mar 20225:29 pmRNSDirector/PDMR Shareholding
1st Mar 202212:56 pmRNSAchilles reports Full Year 2021 Results
18th Feb 20227:00 amRNSCompletion of sale of Gyroscope Therapeutics
8th Feb 202212:05 pmRNSFreeline presents data in Fabry disease
31st Dec 20217:00 amRNSDirectorate Change
22nd Dec 20217:00 amRNSGyroscope to be acquired for up to $1.5 billion
16th Dec 20217:00 amRNSSyncona cornerstones Anaveon Series B
14th Dec 20217:00 amRNSFreeline reports 2022 priorities and guidance
13th Dec 20212:05 pmRNSFreeline presents data in haemophilia B
13th Dec 202112:05 pmRNSAutolus presents positive AUTO1 (obe-cel) data
29th Nov 20217:00 amRNSSyncona co-leads Series B financing in Quell
22nd Nov 20217:00 amRNSSyncona appoints new Directors
12th Nov 20211:56 pmRNSAchilles Presents Data at the SITC Annual Meeting
11th Nov 20217:00 amRNSHalf-year Report
10th Nov 20217:00 amRNSFreeline reports new data and 3rd Quarter Results
9th Nov 20211:31 pmRNSAchilles reports Third Quarter Financial Results
8th Nov 20211:05 pmRNSGyroscope Announces Sanofi Equity Investment
8th Nov 20217:00 amRNSBlackstone Life Science to invest $250m in Autolus
3rd Nov 202111:07 amRNSSyncona leads $87 million financing of Clade
3rd Nov 202111:05 amRNSAutolus reports Q3 2021 Financial Results
26th Oct 20217:00 amRNSNotice of Results
30th Sep 20213:59 pmRNSGyroscope announces additional positive data
17th Aug 20217:00 amRNSFirst Quarter Update
16th Aug 202112:07 pmRNSFreeline Reports Executive Change and Q2 Results
10th Aug 202112:05 pmRNSAchilles reports Second Quarter 2021 Results
5th Aug 202112:05 pmRNSAutolus reports Q2 2021 Financial Results
3rd Aug 20211:16 pmRNSResult of AGM - Replacement
3rd Aug 202112:32 pmRNSResult of AGM
30th Jul 202112:17 pmRNSTotal Voting Rights
27th Jul 20212:41 pmRNSHolding(s) in Company
15th Jul 202112:57 pmRNSIssue of shares pursuant to incentive scheme
1st Jul 202111:54 amRNSPublication of 2021 Annual Report & Notice of AGM
24th Jun 20217:00 amRNSAnaveon doses first patient in Phase I/II study
17th Jun 20217:00 amRNSFinal Results
17th Jun 20217:00 amRNSSyncona announces expansion of leadership team
11th Jun 202112:05 pmRNSAutolus to present additional data in AUTO1
18th May 20217:00 amRNSNotice of Results
18th May 20217:00 amRNSFreeline reports Q1 results
12th May 20213:05 pmRNSAutolus to present additional data in AUTO1

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.